Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

Similar documents
Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion

Vancomycin Drug Class 1

Joint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics

(Max 2 g) = to nearest 250 mg

Evaluation of Vancomycin Continuous Infusion in Trauma Patients

(telavancin) Healthcare Professional s Guide. Version 2, 4 November 2014

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

Haemodialysis central venous catheter-related sepsis management guideline Version 3. NAME M. Letheren Chair Clinical Effectiveness Advisory Group

Cystatin C: A New Approach to Improve Medication Dosing

VANCOMYCIN DOSING AND MONITORING GUIDELINES

ORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Vancomycin: Class: Antibiotic.

D DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.

Adult Institutional Pharmacokinetics Protocol

SHC Vancomycin Dosing Guide

Cubicin A Guide to Dosing

TDM of Aminoglycoside Antibiotics

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel

ICU Volume 11 - Issue 3 - Autumn Series

MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

VANCOCIN CAPSULES (vancomycin hydrochloride)

Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

Cisplatin / Paclitaxel Gynaecological Cancer

GOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist:

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

MANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

PPP 1. Continuation, modification, and discontinuation of a medication

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

Renal Unit. Catheter Related Bacteraemia Guidelines

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations

Gemcitabine + Cisplatin Regimen

GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

SBUH Aminoglycoside Dosing Protocol

Antimicrobial Reference Laboratory

Approved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14

Infective Endocarditis Empirical therapy Antibiotic Guidelines. Contents

StRs and CT doctors in haematology. September Folinic acid dose modified.

Carboplatin + Paclitaxel Cancer of the Cervix

Antimicrobial Reference Laboratory

Clinical Safety & Effectiveness Cohort # 10

An Introduction to Acute Kidney Injury (AKI) An Education Package for Healthcare Professionals in Medical Directorates

Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure

5-FU & Cisplatin + Cetuximab

Guidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PRODUCT INFORMATION TARGOCID

NCCP Chemotherapy Regimen. Carboplatin (AUC 2) Weekly with Radiotherapy (RT)

VANLID Capsules (Vancomycin hydrochloride)

Initiating Aminoglycosides Safely. Last updated: July 2016, Version 5 Questions/Comments?

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches

Analgesia in patients with impaired renal function Formulary Guidance

Vancomycin-associated nephrotoxicity, a case control study

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

Challenges in Therapeutic Drug Monitoring:

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

E 90 C followed by Weekly Paclitaxel

Vancomycin (as hydrochloride)

September 2014 V0.17. Paediatric Daily Fluid Prescription & Balance Chart

Vancomycin Orion , Version 2 Public Summary of the Risk Management Plan

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck

Carboplatin / Gemcitabine Gynaecological Cancer

Guideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use

ELIGIBILITY: small cell or neuroendocrine cancer (pure or mixed) administration of this protocol is restricted to BCCA Cancer Centres

Gemcitabine, Carboplatin and Bevacizumab (gynae)

Modifying Drug Dosing for Patients with Renal Insufficiency

Carboplatin and Gemcitabine

Essential Shared Care Agreement: Lithium

ASHP Therapeutic Position Statements 623

Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia

CISPLATIN Chemo-radiation regimen Gynaecological Cancer

1. NAME OF THE MEDICINAL PRODUCT

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team

Pharmacist and Physician Collaborative Practice Model Improves Vancomycin Dosing in an Intensive Care Unit

Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study

TIP Paclitaxel, Ifosfamide and Cisplatin

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)

Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m 2 Therapy with Radiotherapy

Evaluation of Vancomycin Dosing and Corresponding Drug Concentrations in Pediatric Patients

Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community

Shared Care Guideline

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

ภก.วส นต กาต บ. Use of vancomycin is appropriate or acceptable. FDA Labeled Indication

CRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT

PHA 5128 Spring 2000 Final Exam

Transcription:

VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin is a glycopeptide antibiotic that is active against gram positive organisms, including methicillin resistant Staph. aureus (MRSA). The risk of renal toxicity (and ototoxicity) is increased when prescribed with other nephrotoxic drugs, such as gentamicin. 1,2 2 Intravenous dose of VANCOMYCIN (intermittent bolus dosing) VANCOMYCIN requires determination and prescribing of both of the following: INITIAL LOADING DOSE ONGOING MAINTENANCE DOSE 2.1 BEFORE PRESCRIBING 1. Determine patient ACTUAL BODY WEIGHT 2. Determine patient Creatinine Clearance (see below) Creatinine Clearance (ml/min should be calculated manually using the Cockgroft Gault equation (below)or the online calculator function here. DO NOT use the egfr. Cockcroft Gault equation: Notes for Cockcroft Gault equation: Age (years) Weight (kg) Serum Creatinine (micromols/litre) F = 1.23 in MEN F = 1.04 in WOMEN 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 1 of 8

2.2 PRESCRIBING INITIAL LOADING DOSE : Use Table 1 below to determine the loading dose: Use patient s ACTUAL BODY WEIGHT 1,6 Table 1: VANCOMYCIN LOADING DOSE Actual Body Weight (kg) <60kg 60-90kg >90kg Loading dose 1000mg (1g) 1500mg (1.5g) 2000mg (2g) Adapted from Thomson, AH et al, March 2009 6 2.3 MAINTENANCE DOSE: Based on CALCULATED Creatinine Clearance as indicator of RENAL FUNCTION using Cockcroft Gault equation: see here for online Cockcroft Gault calculator (via medicinescomplete). DO NOT use the egfr. USE the calculated creatinine clearance for the patient in Table 2 below to determine the maintenance dose and dose interval for VANCOMYCIN The first maintenance dose should be given the same number of hours AFTER the LOADING DOSE as the ongoing dosing interval. Table 2: VANCOMYCIN MAINTENANCE DOSE SCALE Creatinine Clearance (ml/min) Dose (mg) Dosing Interval (hours) Dose point 8 >110 1500mg* see below 12 Dose point 7 90-110 1250mg 12 Dose point 6 75-89 1000mg 12 Dose point 5 55-74 750mg 12 Dose point 4 40-54 500mg 12 Dose point 3 30-39 750mg 24 Dose point 2 20-29 500mg 24 Dose point 1 <20 500mg 48 Adapted from Thomson, AH et al, March 2009 6 *UNLESS body weight <45kg: then use MAXIMUM dose of 1.25g (1250mg) until levels have been checked 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 2 of 8

3 Administration Clinical Guidelines for Use of Antibiotics The maximum concentration of vancomycin when prepared for infusion is 5mg/ml. 3,4 Infusions should be given at a rate no greater than 10 mg/min is recommended. 3,4 Rapid infusion may cause severe hypotension (including shock and cardiac arrest), wheezing, dyspnoea, urticaria, pruritus, flushing of the upper body ( red man' syndrome), pain and muscle spasm of back and chest. Stop the infusion if they occur. A longer infusion time or premedication with an antihistamine may limit the reaction. 3 4 VANCOMYCIN LEVEL MONITORING 4.1 Target VANCOMYCIN levels Standard dosing PRE-DOSE LEVELS Target range: 10-15mg/L 1 High dose PRE-DOSE LEVELS for complicated infections Target range: 15-20mg/L 1,5,6,7 Complicated infections include: Bacteraemia (confirmed blood-stream infection) Endocarditis Osteomyelitis Meningitis HAP (Hospital acquired pneumonia) VAP (Ventilator associated pneumonia) Other infections caused by resistant organisms (microbiology will advise). 4.2 Timing of level Levels should be taken within one hour before next dose is due (PRE-DOSE or TROUGH levels) 1 4.3 The intial PRE-DOSE level should be taken: TWICE DAILY (12 hourly) dosing: JUST BEFORE THE FOURTH DOSE ONCE DAILY (24 hourly) dosing: JUST BEFORE THE THIRD DOSE ALTERNATE DAY (48 hourly) dosing: JUST BEFORE THE SECOND DOSE 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 3 of 8

4.4 Do I wait for the level to give the dose or not? Do not wait for the results of the pre-dose (trough) levels before giving the next dose 4.5 How often to repeat blood samples for drug levels TWICE a week if VANCOMYCIN levels are within range and urine output and renal function are STABLE If the dosage has been adjusted, then recheck levels after 2 days: TWICE DAILY (12 hourly) dosing: FOUR DOSES ONCE DAILY (24 hourly)dosing: TWO DOSES ALTERNATE DAY (48 hourly) dosing: ONE DOSE 4.6 Practicalities of taking blood samples for drug levels Send 3.5mL blood in a yellow top (SST) tube Ensure that the following are recorded on the blood form: Time the sample was taken Current dose of VANCOMYCIN Time level taken/hours post last dose. Indication for treatment 4.7 Interpretation of levels: The trough (pre dose) level should be between 10 15mg/L or 15-20mg/L depending on the indication (see section 4.1) If level is outside the desired range, FIRST check for technical explanations; for example: LEVEL taken at INCORRECT TIME INCORRECT timing of DOSAGE Use Table 3 below for guidance on how to adjust VANCOMYCIN dose according to measured pre-dose levels. 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 4 of 8

Table 3: VANCOMYCIN trough level interpretation and maintenance dose adjustment Pre-dose (trough level) Maintenance dose adjustments (Refer to maintenance dose ladder above) < 5 mg/l Move up 2 DOSE POINTS on maintenance dose scale (Table 2) 5 to 10 mg/l Move up 1 DOSE POINT on maintenance dose scale (Table 2) 10 to 15 mg/l For HIGH DOSING of COMPLICATED INFECTIONS (see section 4.1) move up one step on maintenance dose ladder For STANDARD DOSING indications stay at current dose 15 to 20 mg/l Stay at current dose 20 to 25 mg/l Move down 1 DOSE POINT on maintenance dose scale (Table 2) without omitting any doses More than 25 mg/l Omit next dose and decrease by 2 DOSE POINTS on maintenance dose scale (Table 2) > 30 mg/l HOLD VANCOMYCIN DOSING Seek advice from microbiology or an antimicrobial pharmacist Adapted from Vancomycin Prescribing Guidance for: Musgorve Park Hospital (Taunton) and Leeds Teaching Hospitals. 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 5 of 8

5 When to refer to the antibiotic team: Stable therapeutic levels cannot be achieved Patient has severe renal impairment or is on dialysis Patient is not clinically improving 6. Additional Monitoring 6.1 Renal function There is some evidence that high dose vancomycin is associated with a greater risk of renal toxicity. 6,8 For patients with a high trough concentration target (15-20mg/L) renal function MUST be monitored a minimum of twice a week. Patients with new acute kidney injury (AKI) should be referred to the antibiotic team and/or Microbiology for review and/or advice. 6.3 Hearing and balance Where patients are prescribing vancomycin alongside other nephrotoxic drugs (especially aminoglycosides such as GENTAMICIN or AMIKACIN) consider monitoring for signs of ototoxicity (changes to or loss of hearing, changes in balance). 1 6.4 Full blood count Blood dyscrasias have been reported due to VANCOMYCIN therapy, including neutropenia and thrombocytopenia. 4 It is recommended that the FULL BLOOD COUNT is monitored weekly for patients on vancomycin therapy where the duration of the course is greater than 1 week. 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 6 of 8

7. Dialysis patients Please liaise with the Dialysis Unit (5286) for all cases when drugs are administered on dialysis. For Haemodialysis (HD) patients usual dosing is a 1g IV loading dose then a single 500mg IV dose after every dialysis unless the previous level is above 20mg/L. Due to logistics trough vancomycin levels are used from the previous dialysis to decide if the next dose is given. Only in this circumstance is there no need to await the level from the current day before administering the dose. If a trough vancomycin level is above 20mg/L, omit further doses and wait until subsequent trough level is below 20mg/L. Vancomycin will be administered, in the usual case, on the dialysis unit and not on the ward. Supplies of vancomycin will be provided by the ward. Infuse a 1g vancomycin dose over 100 minutes. Type of dialysis Haemodialysis (HD) patients Vancomycin dose 1g IV loading dose and then 500mg IV stat after each HD unless previous level at dialysis is above 20mg/L. The level is recorded from the previous dialysis before each dose is given. On peritoneal dialysis or acute haemodialysis 1g IV loading dose monitor levels every 24 hours. When level is 20mg/L or under give another 1g IV dose. For patients with PD peritonitis, the treatment protocol involves administration of intraperitoneal vancomycin. Please seek advice from the Renal PD Nurses (Ext 5288 / 5286 / 7346). 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 7 of 8

8 References Clinical Guidelines for Use of Antibiotics 1. Rybak et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health- Syst Pharm 2009; 66: 82-88 2. Rybak et al. Nephrotoxicity of vancomyrin, alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy 1990; 25: 679-687 3. Medusa IV monograph for VANCOMYCIN IV. Accessed via http://medusa.wales.nhs.uk/ivguidedisplay.asp (Feb 2015). 4. Summary of Product Characteristic: Vancocin, date of last revision of the text 23 October 2008 (Flynn). Accessed via http://www.medicines.org.uk/emc/medicine/21291 (Feb 2015). 5. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171: 388 416 6. Thomson et al. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. Journal of Antimicrobial Chemotherapy 2009; 63: 1050-1057. 7. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267 84. 8. Jeffres MN, Isakow W, Doherty JA et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillinresistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107 15. 4PHA-GDL-031 Version 4 Adopted as Trust Policy: May 2015 Review Date: May 2017 Page 8 of 8